SALIX PHARMACEUTICALS LTD Contracts & Agreements

FIRST SUPPLEMENTAL INDENTURE (Filed With SEC on April 1, 2015)

AMENDMENTNO. 1 TO AGREEMENT AND PLAN OF MERGER (Filed With SEC on March 16, 2015)

AGREEMENT AND PLAN OF MERGER by and among VALEANTPHARMACEUTICALS INTERNATIONAL, SUN MERGER SUB, INC., VALEANT PHARMACEUTICALS INTERNATIONAL, INC. and SALIX PHARMACEUTICALS,LTD.... (Filed With SEC on February 23, 2015)

LICENSE AGREEMENT BY AND AMONG COWEN HEALTHCARE ROYALTY PARTNERS, L.P. AND SHORE THERAPEUTICS, INC. AND SANTARUS, INC. DATED DECEMBER 21, 2011 TABLE OF CONTENTS (Filed With SEC on February 13, 2015)

8510 Colonnade CenterDrive, Raleigh, NC 27615 www.salix.com ###-###-#### F ###-###-#### (Filed With SEC on January 5, 2015)

Salix Pharmaceuticals, Inc. 8510Colonnade Center Drive Raleigh, NC 27615 (Filed With SEC on November 7, 2014)

Dated 11 September 2014 Dr. FalkPharma GmbH - and - Salix Pharmaceuticals, Inc. SECONDAMENDMENT TO LICENSE AGREEMENT (Mesalamine) (Filed With SEC on November 4, 2014)

Dated 11 September 2014 Dr. FalkPharma GmbH - and - Salix Pharmaceuticals, Inc. FIRSTAMENDMENT TO LICENSE AGREEMENT (Budesonide) (Filed With SEC on November 4, 2014)

AMENDMENT NUMBER THREE TO SUPPLY AGREEMENT (Filed With SEC on October 17, 2014)

AMENDMENT NUMBER FOUR TO SUPPLY AGREEMENT (Filed With SEC on October 17, 2014)

TERMINATION AGREEMENT (Filed With SEC on October 6, 2014)

SETTLEMENT AGREEMENT (Filed With SEC on September 22, 2014)

MANUFACTURING AND SUPPLY AGREEMENT (Filed With SEC on August 8, 2014)

AMENDMENT NO. 8 TOMANUFACTURING AND SUPPLY AGREEMENT (Filed With SEC on August 8, 2014)

COMMERCIALIZATION AGREEMENT (Filed With SEC on August 8, 2014)

SALIX PHARMACEUTICALS, LTD. 2014 STOCK INCENTIVE PLAN TABLE OF CONTENTS (Filed With SEC on June 17, 2014)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on May 5, 2014)

*** CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT (INDICATED BY ASTERISKS) HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT... (Filed With SEC on February 28, 2014)

LICENSE AGREEMENT PREAMBLE (Filed With SEC on February 28, 2014)

SUPPLEMENTAL INDENTURE (Filed With SEC on January 2, 2014)

$750,000,000 SalixPharmaceuticals, Ltd. 6.00% Senior Notes due 2021 Joinder to Registration Rights Agreement (Filed With SEC on January 2, 2014)

CREDITAGREEMENT, dated as of January 2, 2014, among SALIX PHARMACEUTICALS, LTD., asthe Borrower, THE LENDERS PARTY HERETO and JEFFERIES FINANCE LLC, as Administrative Agent and... (Filed With SEC on January 2, 2014)

SALIXPHARMACEUTICALS, LTD. 6.00% SENIOR NOTES DUE 2021 INDENTURE DATED AS OFDECEMBER 27, 2013 U.S. BANK NATIONAL ASSOCIATION, AS TRUSTEE CROSS-REFERENCE TABLE* (Filed With SEC on December 27, 2013)

ESCROW ANDSECURITY AGREEMENT (Filed With SEC on December 27, 2013)

$750,000,000 SALIX PHARMACEUTICALS, LTD. 6.00% Senior Notes due 2021 REGISTRATION RIGHTS AGREEMENT (Filed With SEC on December 27, 2013)

INDEMNITY AGREEMENT (Filed With SEC on December 23, 2013)

AGREEMENT AND PLAN OF MERGER dated as of November 7, 2013 among SALIXPHARMACEUTICALS, LTD., SALIX PHARMACEUTICALS, INC. (solely for purposes of Section 2.1(b) and Sections 4.3(a),... (Filed With SEC on November 7, 2013)

INTRODUCTION (Filed With SEC on November 7, 2013)

Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. THIRD AMENDMENT TO RIFAXIMIN MANUFACTURING AND SUPPLY AGREEMENT between SALIX... (Filed With SEC on August 9, 2013)

Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. SECOND AMENDMENT TO RIFAXIMIN MANUFACTURING AND SUPPLY AGREEMENT between SALIX... (Filed With SEC on May 10, 2013)

Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. FIRST AMENDMENT TO AMENDED AND RESTATED DEVELOPMENT, COMMERCIALIZATION AND LICENSE... (Filed With SEC on May 10, 2013)

Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. AMENDED AND RESTATED LICENSE AGREEMENT dated August 6, 2012 by and between ALFA... (Filed With SEC on November 8, 2012)

Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. EIR SUPPLY AGREEMENT dated August 6, 2012 by and between ALFA WASSERMANN S.P.A. and... (Filed With SEC on November 8, 2012)

Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. AMENDMENT NUMBER TWO TO SUPPLY AGREEMENT (Filed With SEC on November 8, 2012)

Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. TRADEMARK LICENSE AGREEMENT (ALFA TO SALIX) dated August 6, 2012 by and between... (Filed With SEC on November 8, 2012)

Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. TRADEMARK LICENSE AGREEMENT (SALIX TO ALFA) dated August 6, 2012 by and between... (Filed With SEC on November 8, 2012)

Portions of this exhibit marked [*] are omitted and arerequested to be treated confidentially. Salix Pharmaceuticals, Inc. 8510 Colonnade Center Drive Raleigh, North Carolina... (Filed With SEC on November 8, 2012)

SALIX PHARMACEUTICALS, LTD. 2005 STOCK PLAN, AS AMENDED Approved by the Board: May 14, 2012 Approved by the Stockholders: June 14, 2012 (Filed With SEC on May 16, 2012)

SALIX PHARMACEUTICALS, LTD. (A Delaware corporation) $600,000,000 1.50% Convertible Senior Notes Due 2019 PURCHASE AGREEMENT (Filed With SEC on March 16, 2012)

FIRST SUPPLEMENTAL INDENTURE (Filed With SEC on March 16, 2012)

SALIX PHARMACEUTICALS, LTD. as Issuer AND U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of March 16, 2012 1.5% Convertible Senior Notes due 2019 (Filed With SEC on March 16, 2012)

NOTE REPURCHASE AGREEMENT (Filed With SEC on March 16, 2012)

Portions of this exhibit marked [*] are omitted and are requested to be treatedconfidentially. (Filed With SEC on February 28, 2012)

Portions of this exhibit marked [*] are omitted and are requested to be treatedconfidentially. MANUFACTURING AND SUPPLY AGREEMENT (Filed With SEC on February 28, 2012)

THIRD AMENDMENT TO LEASE (Filed With SEC on November 9, 2011)

Portions of this exhibit marked [*] are requested to be treated confidentially. (Filed With SEC on November 9, 2011)

*Portions of this document marked [*] are requested to be treated confidentially. SECOND AMENDMENT TO LEASE (Filed With SEC on May 10, 2011)

FIRST AMENDMENT TO RIFAXIMIN MANUFACTURING AND SUPPLY AGREEMENT between SALIX PHARMACEUTICALS, INC. and LUPIN LTD. Dated as of 31 March 2011 (Filed With SEC on May 10, 2011)

LICENSE AGREEMENT by and between SALIX PHARMACEUTICALS, INC. and PROGENICS PHARMACEUTICALS, INC. PROGENICS PHARMACEUTICALS NEVADA, INC. and EXCELSIOR LIFE SCIENCES IRELAND LIMITED... (Filed With SEC on May 10, 2011)

Portions of this document marked [*] are requested to be treated confidentially. (Filed With SEC on May 10, 2011)

OFFICE LEASE (Filed With SEC on May 10, 2011)

AMENDED AND RESTATED DEVELOPMENT, COMMERCIALIZATION AND LICENSEAGREEMENT between LUPIN LTD. and SALIX PHARMACEUTICALS, INC. Dated as of 31 March 2011 TABLE OF CONTENTS (Filed With SEC on May 10, 2011)

FINISHED PRODUCT MANUFACTURING AND SUPPLY AGREEMENT between SALIX PHARMACEUTICALS, INC. and LUPIN LTD. Dated as of 31 March 2011 TABLE OF CONTENTS (Filed With SEC on May 10, 2011)

LICENSE AGREEMENT between Photocure ASA and Salix Pharmaceuticals, Inc. Dated 19 October 2010 TABLE OF CONTENTS (Filed With SEC on March 1, 2011)

5,500,000 Shares Salix Pharmaceuticals, Ltd. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on November 19, 2009)

DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT Between LUPIN LTD. and SALIX PHARMACEUTICALS, INC. Dated as of September 30, 2009 TABLE OF CONTENTS (Filed With SEC on November 9, 2009)

RIFAXIMIN (Filed With SEC on November 9, 2009)

SALIX PHARMACEUTICALS, LTD. 2005 STOCK PLAN, AS AMENDED (Filed With SEC on June 11, 2009)

Salix Pharmaceuticals, Inc., Mesalamine Controlled Release Capsules (Filed With SEC on May 6, 2009)

Portions of the exhibit marked [*] are requested to be treated confidentially. Dated7 December 2005 (Filed With SEC on March 26, 2009)

* Portions of this document marked [*] are requested to be treated confidentially. (Filed With SEC on March 11, 2009)

$55,000,000 AGGREGATE PRINCIPAL AMOUNT Salix Pharmaceuticals, Ltd. (Filed With SEC on August 22, 2008)

SALIX PHARMACEUTICALS, LTD. as Issuer AND U.S. BANK NATIONAL ASSOCIATION (Filed With SEC on August 22, 2008)

WAIVER AND FIRST AMENDMENT TO CREDIT AGREEMENT (Filed With SEC on August 5, 2008)

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on June 18, 2008)

* Portions of this document marked [*] are requested to be treated confidentially. DATED MARCH 13, 2008 DR. FALK PHARMA GmbH -and- (Filed With SEC on May 7, 2008)

Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. SUPPLY AND DISTRIBUTION AGREEMENT (Filed With SEC on March 14, 2008)

Portions of this exhibit marked [*] are requested to be treatedconfidentially. CO-PROMOTION AGREEMENT (Filed With SEC on November 9, 2007)

Portions of this exhibit marked [*] are requested to be treated confidentially. MASTER PURCHASE AND SALE AND LICENSE AGREEMENT Between (Filed With SEC on May 10, 2007)

Portions of this exhibit marked [*] are requested to be treated confidentially. DATED 16 APRIL 2007 SALIX PHARMACEUTICALS, INC. and DR. FALK PHARMA GmbH LICENSE AGREEMENT 1 TABLE... (Filed With SEC on May 10, 2007)

CREDIT AGREEMENT Dated as of February 22, 2007 among SALIX PHARMACEUTICALS, LTD., as the Borrower, BANK OF AMERICA, N.A., as Administrative Agent, Swing Line Lender and (Filed With SEC on February 28, 2007)

Portions of this exhibit marked [*] are requested to be treated confidentially. DEVELOPMENT AND LICENSEAGREEMENT By and Between DEBIOVISION INC. and SALIX PHARMACEUTICALS, INC.... (Filed With SEC on November 9, 2006)

Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. LICENSEAGREEMENT (Filed With SEC on July 5, 2006)

SALIX PHARMACEUTICALS, LTD. 2005 STOCK PLAN (as amended June 15, 2006) (Filed With SEC on June 16, 2006)

Salix Pharmaceuticals 2006 Board of Directors Compensation Structure (Filed With SEC on March 16, 2006)

SALIX PHARMACEUTICALS, LTD. 2005 STOCK PLAN (Filed With SEC on March 16, 2006)

Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially Dated 7 December 2005 (Filed With SEC on December 13, 2005)

TERMINATION AGREEMENT (Filed With SEC on August 22, 2005)

AGREEMENT AND PLAN OF MERGER (Filed With SEC on June 24, 2005)

Portions of this exhibit marked [*] are requested to be treated confidentially. (Filed With SEC on May 10, 2005)

Salix Pharmaceuticals 2005 Board of Directors Compensation Structure (Filed With SEC on March 15, 2005)

OFFICE LEASE (Filed With SEC on December 13, 2004)

Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. ASSET PURCHASE AGREEMENT (Filed With SEC on August 9, 2004)

SALIX PHARMACEUTICALS, LTD. 1996 STOCK OPTION PLAN (as amended through July 1, 2004) (Filed With SEC on August 9, 2004)

Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. SUPPLY AGREEMENT (Filed With SEC on August 9, 2004)

LICENSE ASSIGNMENT AND CONSENT AGREEMENT (Filed With SEC on August 9, 2004)

ASSIGNMENT OF TRADEMARKS (Filed With SEC on August 9, 2004)

LICENSE AGREEMENT (Filed With SEC on August 9, 2004)

THIRD MODIFICATION TO COMMERCIAL PROMISSORY NOTE AND LOAN AND SECURITY AGREEMENT (Filed With SEC on May 10, 2004)

Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. DATED 24th OF NOVEMBER 2003 DR. FALK PHARMA GmbH - and - SALIX PHARMACEUTICALS,... (Filed With SEC on March 12, 2004)

Portion of this exhibit marked [*] are omitted and are requested to be treated confidentially. (Filed With SEC on March 12, 2004)

SECOND MODIFICATION TO COMMERCIAL PROMISSORY NOTE (Filed With SEC on March 12, 2004)

FIRST MODIFICATION TO COMMERCIAL PROMISSORY NOTE (Filed With SEC on November 14, 2003)

are requested to be treated confidentially. (Filed With SEC on November 14, 2003)

SALIX PHARMACEUTICALS, LTD. COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on November 10, 2003)

OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK (Filed With SEC on January 10, 2003)

Salix Pharmaceuticals, Ltd. (Filed With SEC on January 10, 2003)

DR. FALK PHARMA GmbH -and- SALIX PHARMACEUTICALS, INC. LICENSE AGREEMENT (Filed With SEC on November 14, 2002)

COMMERCIAL PROMISSORY NOTE (Secured, Variable Rate) $7,000,000.00 Raleigh, North Carolina MASTER NOTE September 30, 2002 (Filed With SEC on November 14, 2002)

NEGATIVE PLEDGE AGREEMENT (Filed With SEC on November 14, 2002)

Category

Industry

Companies

Contracts

SALIX PHARMACEUTICALS LTD Contracts & Agreements